Key Points
- CFO Benjamin Hohl sold 6,018 shares for approximately $231,573 at an average price of $38.48, reducing his direct ownership by 13.67% to 38,000 shares. The transaction was conducted under a pre-arranged Rule 10b5-1 trading plan.
- Enliven shares opened at $41.82, below their 50-day and 200-day moving averages, while the company reported a quarterly loss of $0.49 per share versus the $0.39 consensus estimate.
- Analyst sentiment remains broadly positive, with a “Moderate Buy” consensus and an average price target of $75.44, although the clinical-stage biotech remains unprofitable and received a recent downgrade from Zacks Research.
Enliven Therapeutics, Inc. (NASDAQ:ELVN - Get Free Report) CFO Benjamin Hohl sold 6,018 shares of Enliven Therapeutics stock in a transaction on Monday, October 19th. The stock was sold at an average price of $38.48, for a total transaction of $231,572.64. Following the sale, the chief financial officer directly owned 38,000 shares in the company, valued at approximately $1,462,240. This trade represents a 13.67% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Benjamin Hohl also recently made the following trade(s):
- On Thursday, September 17th, Benjamin Hohl sold 6,018 shares of Enliven Therapeutics stock. The stock was sold at an average price of $50.35, for a total transaction of $303,006.30.
- On Monday, August 17th, Benjamin Hohl sold 6,018 shares of Enliven Therapeutics stock. The stock was sold at an average price of $58.58, for a total transaction of $352,534.44.
Enliven Therapeutics Trading Up 1.4%
Shares of NASDAQ ELVN opened at $41.82 on Thursday. The firm has a 50-day simple moving average of $50.93 and a 200-day simple moving average of $48.00. Enliven Therapeutics, Inc. has a 52 week low of $14.78 and a 52 week high of $62.32.
Enliven Therapeutics (NASDAQ:ELVN - Get Free Report) last posted its quarterly earnings results on Wednesday, August 5th. The company reported ($0.49) earnings per share for the quarter, missing the consensus estimate of ($0.39) by ($0.10). Analysts anticipate that Enliven Therapeutics, Inc. will post -1.79 EPS for the current fiscal year.
Trending Headlines about Enliven Therapeutics
Here are the key news stories impacting Enliven Therapeutics this week:
- Positive Sentiment: HC Wainwright reiterated a Buy rating and $73 price target, substantially above the recent trading level. The firm forecasts a 2026 loss of $1.74 per share, slightly better than the $1.81 consensus estimate, providing a positive valuation signal if the company meets expectations.
- Positive Sentiment: HC Wainwright expects quarterly losses of $0.41 per share in Q3 2026 and $0.46 in Q4 2026, followed by losses of $0.48, $0.50, $0.52 and $0.55 per share in the first four quarters of 2027. While still unprofitable, the estimates give investors a forward outlook and support the analyst’s bullish target.
- Neutral Sentiment: The firm projects a full-year 2027 loss of $2.06 per share, underscoring that Enliven remains a development-stage biotechnology company dependent on future clinical and commercial progress rather than current earnings.
- Negative Sentiment: CFO Benjamin Hohl sold 6,018 shares for approximately $231,573, reducing his direct ownership by 13.67%. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan, which makes it less concerning than an unexpected discretionary sale, but it may still weigh on sentiment. SEC insider transaction filing
Wall Street Analyst Weigh In
A number of research firms have commented on ELVN. Zacks Research downgraded shares of Enliven Therapeutics from a "hold" rating to a "strong sell" rating in a report on Tuesday, October 13th. HC Wainwright raised their target price on shares of Enliven Therapeutics from $65.00 to $73.00 and gave the stock a "buy" rating in a research note on Monday. Guggenheim restated a "buy" rating on shares of Enliven Therapeutics in a report on Thursday, October 8th. Barclays began coverage on Enliven Therapeutics in a report on Tuesday, August 18th. They set an "overweight" rating and a $78.00 target price on the stock. Finally, JonesTrading upped their price target on Enliven Therapeutics from $45.00 to $70.00 and gave the company a "buy" rating in a research report on Monday, June 29th. Ten analysts have rated the stock with a Buy rating and two have issued a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $75.44.
Read Our Latest Analysis on Enliven Therapeutics
Institutional Trading of Enliven Therapeutics
A number of hedge funds and other institutional investors have recently modified their holdings of the stock. BlackRock Inc. acquired a new stake in shares of Enliven Therapeutics in the 2nd quarter worth $221,255,000. First Light Asset Management LLC raised its holdings in shares of Enliven Therapeutics by 574.1% during the 2nd quarter. First Light Asset Management LLC now owns 1,360,750 shares of the company's stock worth $69,058,000 after acquiring an additional 1,158,883 shares during the period. Assenagon Asset Management S.A. raised its holdings in shares of Enliven Therapeutics by 276.4% during the 3rd quarter. Assenagon Asset Management S.A. now owns 1,153,973 shares of the company's stock worth $52,898,000 after acquiring an additional 847,399 shares during the period. Rock Springs Capital Management LP boosted its position in shares of Enliven Therapeutics by 3.5% during the 1st quarter. Rock Springs Capital Management LP now owns 826,500 shares of the company's stock valued at $32,399,000 after acquiring an additional 28,095 shares during the last quarter. Finally, Siren L.L.C. acquired a new position in shares of Enliven Therapeutics during the 1st quarter valued at about $29,252,000. 95.08% of the stock is owned by institutional investors and hedge funds.
Enliven Therapeutics Company Profile
(
Get Free Report)
Enliven Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing targeted therapies for patients with cancer. The company uses small-molecule drug discovery and development to pursue treatments designed to address validated cancer targets and improve patient outcomes.
Enliven's pipeline includes ELVN-001, an investigational BCR-ABL1 tyrosine kinase inhibitor being developed for the treatment of chronic myeloid leukemia, and ELVN-002, an investigational HER2 inhibitor intended for use in patients with HER2-positive solid tumors.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
